Intercure Ltd(INCR) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Nov 12 at 4:00 PM ET (Korea 11/13 06:00)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -1 | Insider Own | 39.17% | Shs Outstand | 9.1M | Perf Week | 20.79% |
| Market Cap | 0.05B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 7.9M | Perf Month | -15.14% |
| Enterprise Value | 0.09B | PEG | - | EPS next Q | - | Inst Own | 2.81% | Short Float | 0.06% | Perf Quarter | -19.6% |
| Income | -0.01B | P/S | 0.66 | EPS this Y | - | Inst Trans | -2.27% | Short Ratio | 0.18 | Perf Half Y | -2.93% |
| Sales | 0.08B | P/B | 0.35 | EPS next 5Y | - | ROA | - | Short Interest | 0.00M | Perf YTD | -12.53% |
| Book/sh | 11.38 | P/C | 3.38 | EPS past 3/5Y | - 14.69% | ROE | - | 52W High | -47.28% ($7.55) | Perf Year | -41.47% |
| Cash/sh | 1.18 | P/FCF | - | Sales past 3/5Y | -12.19% 32.88% | ROIC | -7.21% | 52W Low | 27.56% ($3.12) | Perf 3Y | -25.61% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | - | Gross Margin | 8.7% | Volatility(W/M) | 11.73% 6.78% | Perf 5Y | -90.81% |
| Dividend TTM | - | EV/Sales | 1.19 | Sales Y/Y TTM | - | Oper. Margin | -27.06% | ATR (14) | 0.31 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 0.95 | EPS Q/Q | -71.12% | Profit Margin | -13.69% | RSI (14) | 43.65 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.48 | Sales Q/Q | -1.48% | SMA20 | -2.8% ($4.09) | Beta | 1.53 | Target Price | $7.17 |
| Payout | - | Debt/Eq | 0.46 | Earnings | - | SMA50 | -16.77% ($4.78) | Rel Volume | 0.29 | Prev Close | $3.91 |
| Employees | 285 | LT Debt/Eq | 0.2 | EPS/Sales Surpr. | - | SMA200 | -13.01% ($4.58) | Avg Volume(3M) | 0.02M | Price | $3.98 |
| IPO | 2019/1/28 | Option/Short | Yes/Yes | Trades | 53 | Volume | 7,233 | Change | 1.79% |
💊 This is Israel's largest medical cannabis producer and distributor. Through its subsidiary Canndoc, the company produces GMP-certified, pharmaceutical-grade medical cannabis and supplies it directly to patients via a network of pharmacies and clinics across Israel. It is the fastest-growing profitable cannabis company outside of North America and is pursuing expansion into European markets, including Germany.
Over the past 1 year, on the lower side
47% below its 1-year high.
Traded less than usual. That is 29% of its average volume.
INCR has weak earning power
Of every $100 in sales, $27.06 is lost.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $66. Peers typically go for $164.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -90.8%. The S&P 500 did +62% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 2.8%.
Tap to view numbers
It ranks #60 of 83 in the industry
Based on market cap of $52M.
FAQ
What kind of company is INCR?
INCR belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of INCR?
The market cap of INCR is approximately $52M, ranking 4,808 within its sector.
What is the 52-week high and low for INCR?
INCR has recorded a 52-week high of $7.55 and a low of $3.12.
